Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

  • Technology appraisal guidance
  • TA1142
  • Published: 
Download (PDF)

Dupilumab: local formulary information

References

Bhatt SP, Rabe KF, Hanania NA et al. (2023) Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS). New England Journal of Medicine 389(3): 205-214

Bhatt SP, Rabe KF, Hanania NA et al. (2024) Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (NOTUS). New England Journal of Medicine 390(24): 2274-2283

ISBN: 978-1-4731-9414-4

This page was last updated: